Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

Fig. 3

Waterfall plot of maximum percentage changes from baseline in SLD for target lesions. Maximum percentage changes are shown in (a) part 1 (pictilisib + paclitaxel ± bevacizumab), (b) parts 2A and B (2A: pictilisib + paclitaxel; 2B: pictilisib + paclitaxel + bevacizumab), (c) part 2C (pictilisib + paclitaxel + trastuzumab), and (d) part 3 (pictilisib + letrozole). PTEN categories were defined as PTEN loss (PTEN H-score ≥ 0 but ≤ 100) or nonloss (PTEN H-score > 100). CR Complete response, MND Mutation not detectable, PD Progressive disease, PIK3CA Phosphatidylinositol-45-bisphosphate 3-kinase catalytic subunit-alpha, PR Partial response, PTEN Phosphatase and tensin homolog, SD Stable disease, SLD Sum of the longest diameters, UE Unevaluable

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us